Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-001 injection into thermally ablated solid tumors
ISRCTN16103145Phase 2Completed
- Sponsor
- IQVIA
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
01
Overview
Phase 2, open-label, single-arm trial of IP-001 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and soft tissue sarcoma (STS), sponsored by IQVIA. Primary endpoint: Safety and tolerability. Started Dec 2022; status: completed.
02
Drugs
IP-001
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ISRCTN16103145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16103145.